BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 38771260)

  • 1. Radiotherapy and immunology.
    Wang L; Lynch C; Pitroda SP; Piffkó A; Yang K; Huser AK; Liang HL; Weichselbaum RR
    J Exp Med; 2024 Jul; 221(7):. PubMed ID: 38771260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
    Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
    Front Immunol; 2021; 12():799455. PubMed ID: 35069581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy.
    Cao Y; Li W; Wang Z; Pang H
    Tumori; 2021 Aug; 107(4):282-291. PubMed ID: 32734832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
    Hack SP; Zhu AX; Wang Y
    Front Immunol; 2020; 11():598877. PubMed ID: 33250900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments.
    Jachetti E; Sangaletti S; Chiodoni C; Ferrara R; Colombo MP
    Cell Immunol; 2021 Apr; 362():104301. PubMed ID: 33588246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
    Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
    Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance.
    Wei F; Wang D; Wei J; Tang N; Tang L; Xiong F; Guo C; Zhou M; Li X; Li G; Xiong W; Zhang S; Zeng Z
    Cell Mol Life Sci; 2021 Jan; 78(1):173-193. PubMed ID: 32654036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
    Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
    Gorris MAJ; Halilovic A; Rabold K; van Duffelen A; Wickramasinghe IN; Verweij D; Wortel IMN; Textor JC; de Vries IJM; Figdor CG
    J Immunol; 2018 Jan; 200(1):347-354. PubMed ID: 29141863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
    Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
    Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment.
    Mudassar F; Shen H; Cook KM; Hau E
    J Med Imaging Radiat Oncol; 2022 Jun; 66(4):560-574. PubMed ID: 35466515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
    Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
    Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hiding in Plain Sight: Soluble Immunomodulatory Receptors.
    Dahal LN; Schwarz H; Ward FJ
    Trends Immunol; 2018 Oct; 39(10):771-774. PubMed ID: 30195467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sweet Immune Checkpoint Targets to Enhance T Cell Therapy.
    Derosiers N; Aguilar W; DeGaramo DA; Posey AD
    J Immunol; 2022 Jan; 208(2):278-285. PubMed ID: 35017217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors: recent progress and potential biomarkers.
    Darvin P; Toor SM; Sasidharan Nair V; Elkord E
    Exp Mol Med; 2018 Dec; 50(12):1-11. PubMed ID: 30546008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coinhibitory Pathways in Immunotherapy for Cancer.
    Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
    Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
    Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
    Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.